Anebulo Pharmaceuticals Inc. has announced the dosing of the first subjects in its Phase 1 single ascending dose (SAD) study of intravenous (IV) selonabant, a drug under development for the treatment of acute cannabis-induced toxicity. The study is being conducted in healthy young adults and is supported by a collaborative grant from the National Institute on Drug Abuse (NIDA). Selonabant was previously evaluated as an oral treatment in a Phase 2 clinical trial, with the company now prioritizing the IV formulation for potential use in pediatric patients. According to Anebulo, interactions with the U.S. Food and Drug Administration (FDA) are ongoing, with a focus on developing selonabant for children exposed to cannabis toxicity. No efficacy or safety results from the current Phase 1 study have been presented yet; further updates are expected as the study progresses.